These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 11943290)

  • 1. Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects.
    Pascale C; Fornengo P; Epifani G; Bosio A; Giacometto F
    Lancet; 2002 Mar; 359(9312):1153-4. PubMed ID: 11943290
    [No Abstract]   [Full Text] [Related]  

  • 2. Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy.
    Tallarico D; Rizzo V; Di Maio F; Petretto F; Bianco G; Placanica G; Marziali M; Paravati V; Gueli N; Meloni F; Campbell SV
    Angiology; 2003; 54(2):219-27. PubMed ID: 12678198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
    Gao D; Ning N; Niu X; Hao G; Meng Z
    Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic modulation in heart failure: high time for a definitive clinical trial.
    Ashrafian H; Neubauer S
    Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
    [No Abstract]   [Full Text] [Related]  

  • 5. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD; Barr R; Thomas PD; Dyck JR
    Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it?
    Ciotti R; Ucci G; Belotti G; Facchi E; Cremonesi M; Gatti C; Baccheta G
    J Clin Oncol; 2001 Nov; 19(22):4269-70. PubMed ID: 11709572
    [No Abstract]   [Full Text] [Related]  

  • 8. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute pulmonary edema during general anesthesia in a young woman treated with epirubicin].
    Kidmose L; Stolberg EF
    Ugeskr Laeger; 1995 Feb; 157(8):1041-2. PubMed ID: 7879305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetazidine in conditions other than coronary disease, old drug, new tricks?
    Zou H; Zhu XX; Ding YH; Jin QY; Qian LY; Huang DS; Cen XJ
    Int J Cardiol; 2017 May; 234():1-6. PubMed ID: 28256321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy].
    Jensen BV; Nielsen SL; Jensen TS
    Ugeskr Laeger; 1997 Mar; 159(13):1945-9. PubMed ID: 9123633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure.
    Colleoni M; Nelli P; Vicario G; Sgarbossa G; Pancheri F; Manente P
    Eur J Cancer; 1997 Feb; 33(2):321-2. PubMed ID: 9135512
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice.
    Santucci L; Mencarelli A; Renga B; Ceccobelli D; Pasut G; Veronese FM; Distrutti E; Fiorucci S
    Anticancer Drugs; 2007 Oct; 18(9):1081-91. PubMed ID: 17704659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline cardiotoxicity: one size does not fit all!
    Hershman DL; Neugut AI
    J Natl Cancer Inst; 2008 Aug; 100(15):1046-7. PubMed ID: 18664649
    [No Abstract]   [Full Text] [Related]  

  • 17. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
    Ussher JR; Fillmore N; Keung W; Mori J; Beker DL; Wagg CS; Jaswal JS; Lopaschuk GD
    Can J Cardiol; 2014 Aug; 30(8):940-4. PubMed ID: 25064584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
    Daugaard G; Lassen U; Bie P; Pedersen EB; Jensen KT; Abildgaard U; Hesse B; Kjaer A
    Eur J Heart Fail; 2005 Jan; 7(1):87-93. PubMed ID: 15642537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency-domain analysis of the QRS complex after treatment of childhood cancer with anthracycline cytostatics.
    Mladosievicova B; Foltinova A; Luptak I; Petrasova H; Hulin I
    Pediatr Cardiol; 2001; 22(6):478-82. PubMed ID: 11894149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.